Related Experiment Video
Updated: Dec 31, 2025
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
[Research progress in mechanisms for drug-resistance and recurrence in bladder cancer]
1Central Laboratory, Affiliated Haikou Hospital of Xiangya School of Medicine, Central South University, Haikou 570208; Clinical Laboratory, First People's Hospital of Huaihua, Huaihua Hunan 418000, China.
Abstract:
Bladder cancer is a common malignant tumor in the urinary system, and its drug-resistant recurrence has become a major problem in clinical treatment. At present, there is still a lack of molecular markers for effectively predicting bladder cancer resistance. The mechanisms for drug resistance in bladder cancer is very complicated. The common mechanisms of drug resistance include epigenetic modification, abnormal expression level, abnormal regulation of non-coding RNA, production of bladder cancer stem cells, increase of drug efflux and autophagy. The various drug resistance mechanisms of bladder cancer are not independent, but there is a certain relationship between them, which leads to the occurrence of drug resistance. Further study on the mechanisms for bladder cancer resistance is of great importance to overcome these problems.
Insights
Understanding bladder cancer drug resistance is crucial for improving treatment outcomes. This study explores the complex mechanisms, including epigenetic changes and cancer stem cells, contributing to treatment failure and recurrence.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Bladder cancer is a prevalent urinary system malignancy.
- Drug-resistant recurrence poses a significant clinical challenge.
- Effective molecular markers for predicting resistance are lacking.
Purpose of the Study:
- To elucidate the multifaceted mechanisms underlying bladder cancer drug resistance.
- To highlight the interconnectedness of various resistance pathways.
- To emphasize the need for further research into resistance mechanisms.
Main Methods:
- Review and synthesis of current literature on bladder cancer drug resistance.
- Analysis of common resistance mechanisms: epigenetic modification, altered gene expression, non-coding RNA dysregulation, cancer stem cells, drug efflux, and autophagy.
- Examination of the interplay between different resistance mechanisms.
Main Results:
- Bladder cancer drug resistance involves complex, interrelated mechanisms.
- Key contributors include epigenetic alterations, altered gene expression, non-coding RNA, cancer stem cells, drug efflux pumps, and autophagy.
- These mechanisms are not isolated but interact to promote resistance.
Conclusions:
- The intricate network of drug resistance mechanisms in bladder cancer necessitates comprehensive investigation.
- Understanding these pathways is vital for developing strategies to overcome treatment resistance.
- Further research is essential to identify predictive markers and therapeutic targets.
